中文

欧陆通 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-27
ItemAmountY/Y
Revenue¥1.04B+17.3%
Gross profit¥0.18B
Operating income¥-0.01B
Net income¥-0.01B-124.7%
Gross margin17.0%Net margin -1.2%
Revenue Q/Q-3.1%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.86B83.0%
R&D¥0.08B7.9%
SG&A¥0.07B7.0%
Tax & other¥0.00B0.4%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

回盛生物天阳科技海晨股份捷强装备蒙泰高新金春股份维康药业大叶股份迦南智能盛德鑫泰万胜智能龙利得

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies